| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 1月19日，维康制药取得了湖南省工商局颁发的注册号为4300002002856号的《企业法人营业执照》，有限公司依法设立。2003年7月28日，维康制药股东会通过决议，将公司名称变更为“湖南九典制药有限公司”，变更住所为“湖南浏阳生物医药园”。2015年1月17日，湖南九典制药股份有限公司（下称“公司”）召开发起人会议，审议通过了九典有限整体变更为股份有限公司的议案。主要业务为：医药产品的研发、生产和销售及技术转让。该公司主要产品：药品制剂、原料药、药用辅料和植物提取物 （公司的业务及收入分类均按前述口径进行） ，公司现有制剂品种101个、原料药品种16个、药用辅料品种17个、植物提取物品种30个。经营范围为在政策 允许的范围内生产、销售原料药医用制剂保健食品 精细化工。 公司自成立之初一直高度重视产品研发及技术储备工作，目前公司主导产品及主要品种均为自主研发，并成功实现产业化，成为企业发展的源动力，研发实力及产业化能力得到可靠验证。公司实际控制人、董事长朱志宏先生自公司创立即为研发带头人，在长期的研发过程中，公司培养带动了一大批科研力量，建立了一支以博士、硕士、海外归国人才为主体的四百多人的研发技术团队。公司是国家企业技术中心、国家高技术产业化示范工程企业、国家火炬计划重点高新技术企业、湖南省高新技术企业。公司设有药物研究院，其被认定为湖南省企业技术中心，公司建有博士后科研工作站、新型凝胶膏剂湖南省工程研究中心、湖南省呼吸道药物工程技术研究中心等创新平台。 公司以“经皮给药制剂”为核心，针对凝胶贴膏基础技术进行了深广研究，突破了凝胶贴膏的关键共性技术，并实现了凝胶贴膏关键辅料国产替代，推动了外用制剂凝胶贴膏细分领域的发展。目前，公司拥有2个凝胶贴膏类药品注册证书，在研外用制剂产品超10个，其中申报生产1个。公司产品洛索洛芬钠凝胶贴膏（国内首仿）已实现产业化，酮洛芬凝胶贴膏（国内首仿）也即将上市销售。公司也致力于经皮给药领域新型功能材料的开发，攻克经皮给药制剂开发中“卡脖子”关键技术，实现新型材料的开发及产业化；并建立经皮给药制剂研制及评价体系，助力经皮给药制剂产品的开发与上市。 公司是“国家知识产权优势企业”、“湖南省知识产权优势培育企业”、“长沙市知识产权优势培育企业”。目前，公司拥有较为丰富的研发项目储备，多个在研新产品正处于临床前研究、临床研究以及申报生产等各个阶段，能够对现有产品线进行补充，并形成产品系列优势。基于丰富的产品积累，公司可根据产品生命周期、市场需求变化规律以及医药行业发展趋势等因素科学规划，不断优化公司产品结构，促进核心竞争力的提升。 截至目前，公司及子公司共拥有专利114项，其中发明专利41项，实用新型专利8项，外观设计专利65项。报告期内新增发明专利16项，新增实用新型专利2项，外观设计专利1项。新增专利情况详见表一。 截至目前，公司及子公司共拥有各类国内注册商标294项，报告期内新增商标127项，新增商标情况详见表二；公司及子公司拥有著作权登记证书59项，其中计算机软件著作权2项，报告期内无新增著作权登记。 | ||||||||||||||||||||||||
| Main Business | 医药产品的研发、生产和销售 | ||||||||||||||||||||||||
| Legal Representative | 朱志宏 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 曾蕾 | ||||||||||||||||||||||||
| Solicitors | 湖南启元律师事务所 | ||||||||||||||||||||||||
| Auditors | 中审众环会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0731-82831002 | ||||||||||||||||||||||||
| Fax No | 0731-88220260 | ||||||||||||||||||||||||
| Website | www.hnjiudian.com | ||||||||||||||||||||||||
| jiudianzhiyao@163.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 10/10/2017 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.070 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.321 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 5.471 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 8.897B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |